Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ENvue Medical (FEED) Operating Expenses (2017 - 2025)

Historic Operating Expenses for ENvue Medical (FEED) over the last 11 years, with Q3 2025 value amounting to $2.4 million.

  • ENvue Medical's Operating Expenses rose 12085.22% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 11023.38%. This contributed to the annual value of $5.1 million for FY2024, which is 235.27% up from last year.
  • ENvue Medical's Operating Expenses amounted to $2.4 million in Q3 2025, which was up 12085.22% from $3.9 million recorded in Q2 2025.
  • ENvue Medical's 5-year Operating Expenses high stood at $3.9 million for Q2 2025, and its period low was $1.0 million during Q3 2022.
  • In the last 5 years, ENvue Medical's Operating Expenses had a median value of $1.3 million in 2023 and averaged $1.6 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 4911.46% in 2022, then soared by 25762.25% in 2025.
  • Quarter analysis of 5 years shows ENvue Medical's Operating Expenses stood at $2.8 million in 2021, then plummeted by 49.11% to $1.4 million in 2022, then increased by 2.2% to $1.4 million in 2023, then rose by 14.87% to $1.7 million in 2024, then surged by 47.37% to $2.4 million in 2025.
  • Its Operating Expenses was $2.4 million in Q3 2025, compared to $3.9 million in Q2 2025 and $2.2 million in Q1 2025.